Eli Lilly and Novo are developing amylin-targeting drugs to complement GLP-1 obesity medications. Lilly's eloralintide combined with tirzepatide produced 23.3% average weight loss in a Phase 2 trial, substantially more than tirzepatide alone, potentially offering new options for the millions who don't respond adequately to existing GLP-1 drugs.
Eli Lilly and Novo are developing amylin-targeting drugs to complement GLP-1 obesity medicines. Lilly's eloralintide combined with tirzepatide showed 23.3% weight loss versus 14.8% with tirzepatide alone in Phase 2 trials, with potential annual sales forecasted at $23.2 billion by 2035. The approach targets millions of patients who don't respond adequately to existing GLP-1 drugs, though tolerability concerns remain.
Eli Lilly announced that its experimental combination of eloralintide and tirzepatide produced greater weight loss (23.3%) than tirzepatide alone (14.8%) in a Phase 2 trial for obesity and Type 2 diabetes patients. The combo therapy met primary endpoints and plans to advance to Phase 3 trials, though discontinuation rates due to gastrointestinal side effects were higher in the combination group.